Peter S. Goedegebuure
- Immunology top 0.2%
- Immunotherapy and Immune Responses 56
- Immune Cell Function and Interaction 30
- T-cell and B-cell Immunology 25
- Immune cells in cancer 10
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 25
- CAR-T cell therapy research 15
- Molecular Biology top 5%
- RNA Interference and Gene Delivery 9
- Pharmacological Receptor Mechanisms and Effects 8
- Cancer Research top 5%
- Biotechnology top 5%
- Co-authors
- David C. LinehanTimothy J. EberleinBrian A. BeltHong‐Gu JooWilliam E. GillandersWilliam G. HawkinsUdaya LiyanageTodd T. Moore
- Cited by
- ImmunologyOncologyMolecular Biology
- Journals
- Proceedings of the National Academy of Sciences (2 papers)Journal of Clinical Oncology (8 papers)The Journal of Immunology (8 papers)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Peter S. Goedegebuure
96 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Immunology 4.7k
- Oncology 3.7k
- Molecular Biology 1.9k
- Cancer Research 408
- Biotechnology 198
Countries citing papers authored by Peter S. Goedegebuure
This map shows the geographic impact of Peter S. Goedegebuure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter S. Goedegebuure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter S. Goedegebuure more than expected).
Fields of papers citing papers by Peter S. Goedegebuure
This network shows the impact of papers produced by Peter S. Goedegebuure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter S. Goedegebuure. The network helps show where Peter S. Goedegebuure may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter S. Goedegebuure, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 75 | |
| 2 | 2012 | 63 | |
| 3 | Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responsesbreakdown → | 2012 | 759 |
| 4 | 2011 | 43 | |
| 5 | 2011 | 91 | |
| 6 | 2010 | 14 | |
| 7 | 2009 | 351 | |
| 8 | 2007 | 51 | |
| 9 | DNA vaccination targeting mesothelin combined with anti-GITR antibody induces rejection of pancreatic adenocarcinoma | 2006 | 2 |
| 10 | 2003 | 31 | |
| 11 | 2001 | 22 | |
| 12 | 1999 | 55 | |
| 13 | 1999 | 5 | |
| 14 | 1999 | 12 | |
| 15 | 1998 | 26 | |
| 16 | 1997 | 25 | |
| 17 | 1996 | 26 | |
| 18 | 1995 | 97 | |
| 19 | 1995 | 372 | |
| 20 | 1994 | 32 |
About Peter S. Goedegebuure
Peter S. Goedegebuure is a scholar working on Immunology, Oncology and Molecular Biology, having authored 96 papers that have together received 6.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (56 papers), Immune Cell Function and Interaction (30 papers), Cancer Immunotherapy and Biomarkers (25 papers), T-cell and B-cell Immunology (25 papers), CAR-T cell therapy research (15 papers), Immune cells in cancer (10 papers), RNA Interference and Gene Delivery (9 papers) and Pharmacological Receptor Mechanisms and Effects (8 papers). The work is most often cited by research in Immunology (4.7k citations), Oncology (3.7k citations) and Molecular Biology (1.9k citations). Peter S. Goedegebuure has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include David C. Linehan, Timothy J. Eberlein, Brian A. Belt, Hong‐Gu Joo, William E. Gillanders, William G. Hawkins, Udaya Liyanage, Todd T. Moore, Yoshiyuki Tanaka and Steven M. Strasberg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.